DrugLab118 USA Enters U.S. Market with Drink Spiking Detection Programs

TORONTO, ONTARIO, CANADA, September 30, 2026 /CourierPR/ -- DrugLab118 USA, a company with over two decades of forensic expertise, has entered the U.S. market with a suite of rapid drink and drug detection programs aimed at addressing drink spiking and substance misuse on college campuses. Founded in the United Kingdom in 2003, the company brings its advanced technology and extensive experience to the American landscape, positioning itself as a science-led partner for universities and organizations.

The company's initial focus is on higher education, where the need for safety measures is particularly acute. According to a peer-reviewed study of more than 6,000 students across three U.S. universities, 7.8 percent, or roughly one in thirteen, had experienced drink spiking at least once. Additionally, RAINN (Rape, Abuse & Incest National Network) reports that 11.2 percent of college students experience rape or sexual assault through force, violence, or incapacitation. These statistics underscore the pressing need for effective prevention strategies.

DrugLab118 USA offers a range of detection tools, including DrinkDetective for the rapid detection of drugs commonly used in drink spiking, DrugDetective, and FentanylDetective, a rapid cassette test that detects fentanyl and nine of its analogues. The company's technology is already used by police forces, local councils, and venue operators across the United Kingdom and is licensed through partners in Spain. The U.S. portfolio includes these tools, which are designed to make testing available, visible, and familiar wherever risk may arise.

The company's approach extends beyond merely supplying test kits. It plans to work with institutions to design, launch, and maintain prevention programs. The goal is to give people a practical way to respond when a concern arises while supporting a longer-term deterrent that makes drink spiking more difficult to carry out without detection. The proposed model includes DrinkDetective tests for orientation kits, residence halls, and campus venues; visible awareness materials that present testing as an act of care rather than suspicion; guidance for incorporating testing into existing welfare, safe-ride, and bystander-intervention programs; and continued support in subsequent years.

DrugDetective and DrinkDetective hold United States patent protection. Company validation data report 97 to 100 percent agreement with gas chromatography-mass spectrometry (GC/MS) laboratory reference methods. The technology is already used by police forces, local councils, and venue operators across the United Kingdom and is licensed through partners in Spain.

DrugLab118 USA's first priority is higher education. Under Title IX and the Clery Act, U.S. universities carry direct legal and reputational responsibility for student safety and for how they respond to sexual violence. The company's strategy is to make testing familiar and readily available, thereby strengthening prevention efforts and discouraging drink spiking.

After establishing its university program, DrugLab118 USA plans to extend dedicated support to employers, hospitality, and nighttime-economy venues, and other public and private organizations. University leaders, campus safety teams, Title IX coordinators, and organizations addressing drink spiking or substance misuse may contact DrugLab118 USA to discuss a potential partnership.

The company's DrinkDetective and DrugDetective tools are designed to address a closely related risk: more than 250,000 Americans have died from fentanyl since 2021, much of it mixed unknowingly into other substances. By making testing available, DrugLab118 USA aims to contribute to a broader effort to protect public health and safety.